CRISPR Therapeutics Stock Upgrades to 91 RS Rating But Not Near Buy Zone
-
CRISPR Therapeutics (CRSP) saw its Relative Strength (RS) Rating improve from 87 to 91 on Tuesday. Stocks with RS Ratings above 80 tend to be market leaders.
-
CRISPR Therapeutics showed 0% earnings growth last quarter. Sales fell 100%.
-
The stock is ranked #44 among its Medical-Biomed/Biotech industry peers in terms of RS Rating.
-
Top stocks in the industry group include Amphastar Pharm, Neurocrine Biosciences, and Catalyst Pharmaceuticals.
-
Now is not an ideal time to buy CRISPR as it's not near a proper buy zone, but monitor if it offers a valid buy point.